[Use of the Gepon immunomodulator for ulcerative colitis treatment].
Observational study · 2005
- What was studied
- 36 patients with resistant distal ulcerative colitis
- Main finding
- In a 36-person uncontrolled report of resistant distal ulcerative colitis, 83.3% had clinical and endoscopic improvement after Gepon.
Within the treated cohort; no untreated response rate supplied
Reported findings and study design
In a 36-person uncontrolled report of resistant distal ulcerative colitis, 83.3% had clinical and endoscopic improvement after Gepon.
36 patients with resistant distal UC; adjunctive immunomodulation.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Clinical and endoscopic amelioration | 83.3% | Within the treated cohort; no untreated response rate supplied |
| Participants | 36 |
The percentage is an uncontrolled response proportion, not a placebo-adjusted remission rate. Long-term relapse and adverse-event rates are not quantified.
Source for these results ↗ · Reviewed 2026-11-01
Study limitations and source details
Study limitations
- No concurrent comparator is described; the reported response proportion is not an effect versus placebo or standard care.
- Full methods, reporting completeness and independent replication remain to be appraised.
Source details
Original journal report
Primary citation and indexed abstract reviewed through Europe PMC. Full article not appraised.
Abstract reviewed
Sources checked
Citation
Malakhova NS, Pichugin AV, Khalif IL, Ataullakhanov RI. [Use of the Gepon immunomodulator for ulcerative colitis treatment]. Eksperimental'naia i klinicheskaia gastroenterologiia = Experimental & clinical gastroenterology · PMID 15991847